DURATION 1 [28] | From exenatide twice daily 10 µg | To exenatide ER 2.0 mg |
Further decreases in HbA1c levels of 0.2%-point. | ||
LEAD 6 [29] | From exenatide twice daily 10 µg | To liraglutide 1.8 mg |
Further decreases in HbA1c levels of 0.3%-point and weight decreased by 0.9 kg. | ||
CIBELES Project [30] | From another GLP-1RA | To exenatide ER |
Further decreases in HbA1c levels of 0.4%-point with no significant changes in weight. | ||
Visaria et al. [31] | From another GLP-1RA | To OW semaglutide |
Further decreases in HbA1c levels of 1.3%-point. | ||
REALiSe-DM [32] | From either liraglutide or dulaglutide | To OW semaglutide |
Further decreases in HbA1c levels of 0.7%-point. The mean reduction in weight was 1.6 kg following the switch. | ||
Watanabe et al. [33] | From exenatide twice daily | To exenatide ER |
Further decreases in HbA1c levels of 0.2%-point over 24 weeks. Incidence of hypoglycemia was also significantly reduced. No significant changes in weight. | ||
Goncalves and Bell study [34] | From liraglutide 1.8 mg | To OW semaglutide average dose 0.76 |
HbA1c decreased from 7.46% ± 1.36% to 6.68% ± 1.00% The number of patients requiring insulin dropped from 16 to 13. Weight dropped from 110.6 ± 20 to 106 ± 27 kg. | ||
Overgaard et al. modeling study [35] | From another GLP-1RA | To OW semaglutide |
More reductions in HbA1c Further weigh reduction. |